Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Auristatin PE

HY-14672

(Soblidotin; TZT 1027; TZT-1027; TZT1027)

Auristatin PE

Auristatin PE Chemical Structure

Auristatin PE is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $541 In-stock
1 mg $140 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
25 mg $1000 In-stock
50 mg $1500 In-stock
100 mg Get quote
200 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €530 In-stock
1 mg €137 In-stock
5 mg €343 In-stock
10 mg €490 In-stock
25 mg €980 In-stock
50 mg €1470 In-stock
100 mg Get quote
200 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Auristatin PE
Cat. No.: HY-14672

Auristatin PE Data Sheet

Related Compound Libraries

Biological Activity of Auristatin PE

Auristatin PE is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization.
Target: Tubulin[1]
InVitro: Auristatin PE (TZT-1027) is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. Auristatin PE exhibits antitumor activity against p-glycoprotein-overexpressing cell lines established from colon cancer H116 and breast cancer-resistant protein-positive cell lines established from lung cancer PC-6, and is more potent than Vincristine, Paclitaxel, and Docetaxel against these cell lines[1]. Auristatin PE (Soblidotin) is a synthetic analog of dolastatin 10 which inhibits the growth of several tumoral cell lines and induces caspase-3-dependent apoptosis. Auristatin PE also shows antitumoral activity in Vincristine-, Docetaxel-, and Paclitaxel-resistant tumors, which makes it a potential chemotherapy drug for use in tumors which do not respond to other microtubule inhibitors[2].
InVivo: Intravenous injection of Auristatin PE (TZT-1027) has been shown to potently inhibit the growth of P388 leukemic cells and several solid tumors in mice, and to prolong the survival of the animals, and its antitumor efficacy has been shown to be superior or comparable to that of the reference agents Dolastatin 10, Cisplatin, Vincristine, and 5-Fluorouracil. Furthermore, in xenograft models, Auristatin PE reduces intratumoral blood perfusion 1 to >24 h after its administration, thereby producing hemorrhagic necrosis of the tumors[1]. Auristatin PE (Soblidotin) shows antivascular effects in tumoral models overexpressing VEGF and in murine colon tumors, with an increase in vascular permeability, vessel closure, and widespread hemorrhage[2]. Mice bearing subcutaneous HT-29 tumors (200 mm3) are dosed every 7 days with Auristatin PE (0.5 or 1.0 mg/kg) for a total of four cycles. Under such conditions, Auristatin PE (TZT-1027) inhibits the growth of HT-29 xenografts in a dose-dependent manner. Coadministration of Auristatin PE does not interfere with the PD184352-induced suppression of ERK1/2 phosphorylation. Immunostaining for Ki-67 as a marker for proliferating cells confirmed that the number of such cells in tumor sections is decreased greatly at 24 hours after the initial dosing with PD184352 compared with that apparent for vehicle-treated tumors . Auristatin PE treatment alone increases the number of TUNEL-positive cells in HT-29 xenografts by 24 hours in a dose-dependent manner, and this effect is enhanced by coadministration of PD184352[3].

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 701.98 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₃₉H₆₇N₅O₆
CAS No 149606-27-9
Solvent & Solubility

10 mM in DMSO; Methanol: ≥ 44 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.4245 mL 7.1227 mL 14.2454 mL
5 mM 0.2849 mL 1.4245 mL 2.8491 mL
10 mM 0.1425 mL 0.7123 mL 1.4245 mL

References on Auristatin PE

Inhibitor Kit

Related Microtubule/Tubulin Products

  • 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • 10-Oxo Docetaxel

    10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

  • 2-Methoxyestradiol

    2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.

  • 4'-Demethylepipodophyllotoxin

    4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.

  • 7-Epi-10-oxo-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

  • 7-Epi-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

  • 7-xylosyltaxol

    7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.

  • ABT-751

    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.

  • Auristatin E

    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

  • Auristatin F

    Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.

MORE